7 questions you might have about biosimilarity, answered

7 questions you might have about biosimilarity, answered
David Rosen, FDA practice group leader and co-chair of the Life Sciences Industry Team at Washington, D.C.-based Foley and Lardner, LLP, has more than 35 years of experience in various aspects of biopharmaceutical regulation, with a strong focus on generic drugs.

BioPharma Dive spoke to Rosen about the evolving role of biosimilars as an important part of the therapeutic landscape. Here, he weighs in not only on the new legislation, but also issues related to biosimilar approval, as well as naming conventions and how ultimately, the most important factors are safety, efficacy, and overall patient well-being.

If you prefer to receive a copy via email contact us at enquiryIQPC@iqpc.com with the subject line '7 questions you might have about biosimilarity, answered  - Interview Request'


Please note: That all fields marked with an asterisk (*) are required.